Pancreatic Cancer Research

ResearcherMasaryk Memorial Cancer InstituteActive in the last 2 years

Petr Karásek

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-1772-5709; OpenAlex author ID A5090083240. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 9

  1. Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum. Co-author DOI 10.1038/s43856-026-01445-5↗
  2. Current diagnostic and treatment options for pancreatic cancer in 2024. First author PMID 39138013↗
  3. Lipidomic profiling of human serum enables detection of pancreatic cancer. Co-author DOI 10.1038/s41467-021-27765-9↗
  4. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical… Co-author DOI 10.21873/cgp.20090↗
  5. Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0159255↗
  6. [Prognostic and Predictive Factors for Pancreatic Adenocarcinoma]. Co-author DOI 10.14735/amko2016336↗
  7. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13000-015-0272-6↗
  8. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine… Co-author DOI 10.1016/j.ejca.2013.04.002↗
  9. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion. First author PMID 22187705↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Radim Němeček · 1 shared paper, 2024 · strength 0.46
  2. Bohuslav Melichar · 2 shared papers, 2022–2026 · strength 0.35
  3. Ondřej Peterka · 2 shared papers, 2022–2026 · strength 0.35
  4. Michal Holčapek · 2 shared papers, 2022–2026 · strength 0.35
  5. Markéta Hermanová · 5 shared papers, 2011–2018 · strength 0.34
  6. Milan Vošmik · 1 shared paper, 2026 · strength 0.24
  7. Martin Loveček · 1 shared paper, 2026 · strength 0.24
  8. Jan Trna · 1 shared paper, 2026 · strength 0.24
  9. Beatrice Mohelníková-Duchoňová · 1 shared paper, 2026 · strength 0.24
  10. Zdeněk Kala · 3 shared papers, 2011–2018 · strength 0.15
  11. Jan Hlavsa · 2 shared papers, 2015–2018 · strength 0.12
  12. Vladimír Procházka · 2 shared papers, 2015–2018 · strength 0.12
  13. Ondřej Slabý · 2 shared papers, 2015–2018 · strength 0.12
  14. Petra Vychytilova‐Faltejskova · 2 shared papers, 2015–2018 · strength 0.12
  15. Igor Kišš · 2 shared papers, 2015–2018 · strength 0.12
  16. Pavel Škrha · 1 shared paper, 2022 · strength 0.11
  17. Jan Škrha · 1 shared paper, 2022 · strength 0.11
  18. Denise Wolrab · 1 shared paper, 2022 · strength 0.11
  19. Renata Veselská · 2 shared papers, 2011–2016 · strength 0.09
  20. Natalia Gabło · 1 shared paper, 2018 · strength 0.08
  21. Jiří Lenz · 2 shared papers, 2011–2015 · strength 0.07
  22. Jan Skoda · 1 shared paper, 2016 · strength 0.07
  23. Philippe R Rougier · 1 shared paper, 2013 · strength 0.03
  24. Armando Santoro · 1 shared paper, 2013 · strength 0.03
  25. Hanno B. Riess · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.